Skip to Main Content

It’s been just over a month since Amgen and Novartis ended two studies of an experimental Alzheimer’s treatment early, the latest in a long string of failures in Alzheimer’s drug development.

There is still no effective treatment for the disease. But as the population ages, the already significant need for an Alzheimer’s treatment is only growing more urgent, said Dr. David Reese, executive vice president of research and development at Amgen.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.